ZE 74-0282 Market Summary

Key Factors Driving ZE 74-0282 Growth

1. Highly selective targeting of mutant JAK2 V617F may offer a superior therapeutic index:

ZE74-0282 is designed to selectively inhibit the JAK2 V617F mutation while sparing wild-type JAK2, addressing one of the key limitations of currently approved JAK inhibitors, which suppress both mutant and normal hematopoietic signaling. Preclinical studies demonstrated up to 500-fold selectivity for mutant JAK2 over wild-type JAK2 and potent inhibition of STAT5 phosphorylation in JAK2 V617F-mutant cells, suggesting the potential for improved efficacy with reduced hematologic toxicity.

2. Potential disease-modifying activity in myeloproliferative neoplasms:

In preclinical whole-blood assays using samples from patients with JAK2 V617F-positive myelofibrosis, ZE74-0282 preferentially inhibited malignant myeloid cells while largely sparing non-mutant cells. The compound also showed greater suppression of mutant colony formation and stronger antitumor activity than fedratinib in xenograft models, supporting its potential to modify disease biology rather than providing only symptomatic control.

3. Advancement into first-in-human clinical trials reduces development risk:

Eilean Therapeutics advanced ZE74-0282 into first-in-human clinical development after completing a comprehensive nonclinical package demonstrating favorable pharmacology, safety, pharmacokinetics, and oral bioavailability. In addition to the healthy volunteer study, a Phase I dose-escalation and expansion trial has begun enrolling approximately 60 patients with JAK2 V617F-positive hematologic malignancies, including PV and MF, with study completion expected in 2028. Progress into clinical testing represents a significant milestone toward commercialization.

4. Large addressable market across multiple JAK2-driven diseases:

The JAK2 V617F mutation is the predominant driver mutation in polycythemia vera and is also present in a substantial proportion of essential thrombocythemia and primary myelofibrosis patients. A therapy capable of selectively targeting this mutation could potentially be developed across several MPN indications, substantially expanding the commercial opportunity beyond a single disease.

5. Convenient once-daily oral therapy may improve adoption:

ZE74-0282 is being developed as a once-daily oral small molecule, an administration route that is well suited for chronic management of MPNs. Combined with its mutant-selective mechanism, oral dosing could support long-term adherence and facilitate use in both earlier- and later-line treatment settings if clinical efficacy and safety are confirmed.

ZE 74-0282 Recent Developments

In December 2025, Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant and is being developed as a differentiated therapeutic candidate for myeloproliferative neoplasms, including myelofibrosis.

“ZE 74-0282 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ZE 74-0282 for potential indication like Myeloproliferative disorders and Polycythaemia vera in the 7MM. A detailed picture of ZE 74-0282’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ZE 74-0282 for potential indications. The ZE 74-0282 market report provides insights about ZE 74-0282’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZE 74-0282 performance, future market assessments inclusive of the ZE 74-0282 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZE 74-0282 sales forecasts, along with factors driving its market.

ZE 74-0282 Drug Summary

ZE 74-0282 is an investigational small-molecule therapeutic being developed by Zentiva for the treatment of polycythemia vera (PV). Although detailed information regarding its molecular target and mechanism of action has not been publicly disclosed, the compound is being evaluated as a potential oral therapy aimed at controlling the excessive production of blood cells that characterizes PV, with the goal of maintaining hematocrit within target levels, reducing the need for therapeutic phlebotomy, and lowering the risk of thrombotic complications. ZE 74-0282 is currently in the early stages of clinical development, where its safety, pharmacokinetics, tolerability, and preliminary efficacy are being assessed in patients with PV. As an investigational candidate, publicly available clinical and mechanistic data remain limited, and its future role in the treatment landscape will depend on the outcomes of ongoing and subsequent clinical studies demonstrating meaningful efficacy, safety, and differentiation from established therapies such as JAK inhibitors and interferon-based treatments. The report provides ZE 74-0282’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ZE 74-0282 Market Report

The report provides insights into:

• A comprehensive product overview including the ZE 74-0282 MoA, description, dosage and administration, research and development activities in potential indication like Myeloproliferative disorders and Polycythaemia vera.
• Elaborated details on ZE 74-0282 regulatory milestones and other development activities have been provided in ZE 74-0282 market report.
• The report also highlights ZE 74-0282‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ZE 74-0282 market report also covers the patents information, generic entry and impact on cost cut.
• The ZE 74-0282 market report contains current and forecasted ZE 74-0282 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ZE 74-0282 market report also features the SWOT analysis with analyst views for ZE 74-0282 in potential indications.

Methodology

The ZE 74-0282 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZE 74-0282 Analytical Perspective by DelveInsight

• In-depth ZE 74-0282 Market Assessment

This ZE 74-0282 sales market forecast report provides a detailed market assessment of ZE 74-0282 for potential indication like Myeloproliferative disorders and Polycythaemia vera in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZE 74-0282 sales data uptil 2034.

• ZE 74-0282 Clinical Assessment

The ZE 74-0282 market report provides the clinical trials information of ZE 74-0282 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ZE 74-0282 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ZE 74-0282 Market Potential & Revenue Forecast

• Projected market size for the ZE 74-0282 and its key indications
• Estimated ZE 74-0282 sales potential (ZE 74-0282 peak sales forecasts)
• ZE 74-0282 Pricing strategies and reimbursement landscape

ZE 74-0282 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ZE 74-0282 Market positioning compared to existing treatments
• ZE 74-0282 Strengths & weaknesses relative to competitors

ZE 74-0282 Regulatory & Commercial Milestones

• ZE 74-0282 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ZE 74-0282 Clinical Differentiation

• ZE 74-0282 Efficacy & safety advantages over existing drugs
• ZE 74-0282 Unique selling points

ZE 74-0282 Market Report Highlights

• In the coming years, the ZE 74-0282 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ZE 74-0282 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZE 74-0282’s dominance.
• Other emerging products for Myeloproliferative disorders and Polycythaemia vera are expected to give tough market competition to ZE 74-0282 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZE 74-0282 in potential indications.
• Analyse ZE 74-0282 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ZE 74-0282 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZE 74-0282 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ZE 74-0282? How strong is ZE 74-0282’s clinical and commercial performance?
• What is ZE 74-0282’s clinical trial status in each individual indications such as Myeloproliferative disorders and Polycythaemia vera and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZE 74-0282 Manufacturers?
• What are the key designations that have been granted to ZE 74-0282 for potential indications? How are they going to impact ZE 74-0282’s penetration in various geographies?
• What is the current and forecasted ZE 74-0282 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ZE 74-0282 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZE 74-0282 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ZE 74-0282? What is the duration of therapy and what are the geographical variations in cost per patient?